Shinpoong Pharmaceutical Co (XKRX:019170) Total Liabilities : ₩77,237 Mil (As of Mar. 2024)

View and export this data going back to 1990. Start your Free Trial

What is Shinpoong Pharmaceutical Co Total Liabilities?

Shinpoong Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2024 was ₩77,237 Mil.

Shinpoong Pharmaceutical Co's quarterly Total Liabilities increased from Sep. 2023 (₩76,020.81 Mil) to Dec. 2023 (₩79,301.50 Mil) but then declined from Dec. 2023 (₩79,301.50 Mil) to Mar. 2024 (₩77,237.04 Mil).

Shinpoong Pharmaceutical Co's annual Total Liabilities declined from Dec. 2021 (₩38,025.38 Mil) to Dec. 2022 (₩30,777.77 Mil) but then increased from Dec. 2022 (₩30,777.77 Mil) to Dec. 2023 (₩79,301.50 Mil).

Shinpoong Pharmaceutical Co Total Liabilities Historical Data

The historical data trend for Shinpoong Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shinpoong Pharmaceutical Co Total Liabilities Chart

Shinpoong Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

170,985.48

112,819.61

38,025.38

30,777.77

79,301.50

Shinpoong Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															62,772.02	61,786.84	76,020.81	79,301.50	77,237.04

Shinpoong Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Shinpoong Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	76384.881	+	(218.961	+	1589.81
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	1107.843)
	=	79,301

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	350083.64	-	270782.145
	=	79,301

Shinpoong Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	74316.078	+	(189.247	+	1589.811
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	1141.907)
	=	77,237

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	345827.77	-	268590.726
	=	77,237

Shinpoong Pharmaceutical Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Shinpoong Pharmaceutical Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Shinpoong Pharmaceutical Co (XKRX:019170) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shinpoong Pharmaceutical Co Ltd (XKRX:019170) » Definitions » Total Liabilities

Traded in Other Exchanges

019175:Korea

Address

161, Yeoksam-ro, Gangnam-gu, Seoul, KOR, 06246

Website

https://shinpoong.co.kr

Shinpoong Pharmaceutical Co Ltd specializes in manufacturing remedy drugs and also active pharmaceutical ingredients and finished products. Its products include Newsicam, Caravenal, Roxagen, Clamoxin duo, Ceroxim, and Clocin. The firm's production facilities are located at Gyeonggi-do and Cheongwon-gun.

Shinpoong Pharmaceutical Co (XKRX:019170) Headlines

No Headlines